Oligotherapeutics: status quo and future outlook

Oligonucleotide therapeutics offer promising treatments for rare and genetic diseases, with 22 US FDA-approved drugs to date. This interactive infographic covers their types, leading developers in 2025, ongoing trials, key challenges, and includes expert insights from Christopher Serpell (Associate Professor of Drug Discovery, UCL), David W. Salzman (Gatehouse Bio), and Nizar Saad (Research Assistant Professor, Nationwide Children’s Hospital). NEW INTERACTIVE FORMAT Listen to our expert speakers. Read the summary. Focus in on the data. It has never been easier to quickly access the information you want. All in one place—at the click of a button.

Please enter your email to access content Read now